Francie Barron


VP R&D and Regulatory Affairs
Nanomed
San Diego, California

Directing research, development, and regulatory affairs at Nanomedical Diagnostics, Dr. Barron earned her PhD in Cell Biology, Stem Cells, and Development at the University of Colorado Denver Anschutz Medical Campus. Dr. Barron brings 19 years of a rich and diverse research background in academic, pharmaceutical, and regulatory settings to her role optimizing biological systems and directing regulatory strategies for clinical products. Prior to graduate school, Dr. Barron was a manager at the Ludwig Institute for Cancer Research, where she designed and produced over 50 novel antibodies for C. elegans targets, optimizing them for in vivo and in vitro assays. Her doctorate work led to the elucidation of a novel signaling pathway that could be linked to craniofacial defects in pediatric patients. As a postdoc at Stanford, Dr. Barron received a NIH training grant award to develop a new in vitro drug screening process to assess cardiac safety of novel compounds on iPSC-derived human cardiomyocytes. While at Nanomedical Diagnostics, Dr. Barron has written several peer-reviewed publications and white papers to support technology and product development, and was awarded a DARPA grant to develop therapeutic drug monitoring at the hospital bedside. Her leadership has led to multiple successful product launches and novel nanotechnology-enabled applications that opened up broader customer markets. Dr. Barron’s forward thinking has helped to shape new strategic alliances with pharma and academic partners that will have a large impact on Agile as a clinical diagnostic. With a proven track record and a deep understanding of biology and its application to life science and clinical markets, Dr. Barron is uniquely equipped to guide successful research and development projects towards commercial success.

Send Email to Francie Barron